作者姓名：BioLife Team

Not every Chinese device company needs U.S. clinical data support at the very beginning. The real question is not simply whether data is needed. The real question is what the company is trying to achieve, where the evidence gap is, and what problem needs to be solved next. Without that clarity, companies often misjudge both the value and the timing of clinical data support.

Conversations about health AI over the past few years have focused heavily on model capability: whether the algorithm is advanced enough, whether performance is strong enough, and whether the product can clear a regulatory path. But as we move deeper into 2026, a more fundamental shift is taking place. For many health AI products, the real differentiator is no longer simply whether the model looks strong. It is whether the product can continuously build and demonstrate real-world evidence. That is increasingly becoming the new gatekeeper.